Vosoritide Treatment in Children with Hypochondroplasia: Three-Year Results from a Phase 2 Extension Trial.
Vosoritide treatment in children with hypochondroplasia showed sustained growth improvements over three years, but results should be interpreted cautiously due to the small sample size.
Where it sits
this study against the rest of the vosoritide corpusSummary and findings
This study measured the effects of vosoritide on growth in children with hypochondroplasia over three years. Thirteen participants who previously responded to treatment continued receiving daily subcutaneous vosoritide at a dose of 15 μg/kg/day. The study reported increases in height and annualized growth velocity.
Abstract
<h4>Purpose</h4>Vosoritide is a C-type natriuretic peptide analog approved for achondroplasia and under investigation for selected genetic causes of short stature. We previously reported the 12-months results of a phase 2 trial in children with hypochondroplasia (NCT04219007). Here, we report safety and efficacy outcomes from the three-year extension phase.<h4>Methods</h4>After completing a 6-month observation period followed by 12 months of daily subcutaneous vosoritide (15 μg/kg/day), participants with an increase in annualized growth velocity (AGV) >1.6 cm/year compared to baseline were eligible to continue in an open-label extension phase.<h4>Results</h4>Thirteen participants entered the extension phase and completed three years of treatment. Mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching -2.64±0.79 SD on the CDC growth charts. A similar increase was observed on the hypochondroplasia-specific charts (0.83 SD). Mean AGV increased from 4.27±0.70 cm/year at baseline to 7.24±0.80 cm/year at Year 1 and remained above baseline at Year 3 (6.13±1.27 cm/year). No new safety concerns were identified.<h4>Conclusion</h4>Vosoritide was associated with sustained improvements in growth in a selected cohort of initial good responders with hypochondroplasia. The treatment was well tolerated. Limitations of the extension study include selection bias and a small sample size.
Background
This paper addresses the long-term effects of vosoritide, a C-type natriuretic peptide analog, in children with hypochondroplasia. Previous studies have indicated short-term efficacy, but longer-term data are necessary to assess sustained benefits and safety. Understanding the impact of vosoritide on growth in this population is crucial for evaluating its potential role in treating genetic causes of short stature.
Methods
The study design involved an open-label extension phase following a 6-month observation period and 12 months of daily subcutaneous vosoritide at a dose of 15 μg/kg/day. The population consisted of children with hypochondroplasia who had shown an increase in annualized growth velocity greater than 1.6 cm/year compared to baseline. The primary outcome measures included changes in height SDS and annualized growth velocity over three years.
Results
The primary endpoint showed that mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching -2.64±0.79 SD. Mean annualized growth velocity increased from 4.27±0.70 cm/year at baseline to 7.24±0.80 cm/year at Year 1, and remained above baseline at Year 3 with a value of 6.13±1.27 cm/year. No new safety concerns were reported during the study.
Interpretation
These findings suggest that vosoritide may provide sustained improvements in growth metrics for children with hypochondroplasia, although the effect size may not be clinically significant given the small sample size. The lack of new safety concerns is a positive aspect, but the study's limitations, including selection bias and the small n of 13 participants, restrict the ability to generalize these results to a broader population. Further studies with larger cohorts are necessary to confirm these outcomes.
Key findings
- Mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching -2.64±0.79 SD.
- Mean AGV increased from 4.27±0.70 cm/year at baseline to 7.24±0.80 cm/year at Year 1 and remained at 6.13±1.27 cm/year at Year 3.
- No new safety concerns were identified.
Limitations
- small sample size of n=13
- selection bias in participant eligibility
- open-label design may introduce bias
- no control group for comparison